Remote monitoring of patients with rheumatoid arthritis using a personal messenger

Abstract

BACKGROUND: Remote medical technologies are a promising way to monitor patients during disease diagnosis, treatment, and subsequent rehabilitation. This paper reviews the clinical implementation and effectiveness of digital tools for remote monitoring and treatment control in patients with rheumatoid arthritis.

AIM: The aim of the study was to evaluate safety, efficacy and technological features of monitoring patients with rheumatoid arthritis using a remote monitoring platform.

MATERIALS AND METHODS: The prospective, non randomized, controlled study included patients over 18 years of age with moderately to severely active rheumatoid arthritis who were discharged from the hospital for outpatient monitoring. Patients were divided into two groups for remote and in person monitoring. Data for remote patient monitoring was collected through questionnaires using a Telemedbot Personal Messenger. The authors also used the Health Assessment Questionnaire (HAQ) to assess daily life functioning in patients with rheumatoid arthritis; the European Quality of Life Questionnaire EQ-5D questions to assess patient adherence, duration of morning stiffness, number of painful and swollen joints; and a visual analog scale to assess the overall condition. After 6 months, efficacy of rheumatoid arthritis treatment was assessed in both groups using the DAS28 index.

RESULTS: The remote monitoring program involved 30 patients for 6 months. The in person monitoring group also included 30 people. After 6 months, patients using the Telemedbot Personal Messenger achieved low rheumatoid arthritis activity and remission more often than the second group (p=0.049). In the remote monitoring group, 9 (30.0%) and 11 (36.7%) patients achieved remission and low disease activity, compared to 3 (10.0%) and 8 (26.7%) patients in the in person monitoring group. Therefore, 20 (66.7%) people in the remote monitoring group were able to control the disease, while only 11 (36.7%) patients in the in person monitoring group were able to do so.

CONCLUSIONS: Remote monitoring using the Telemedbot Personal Messenger can be considered a potential way to increase the availability of medical care and efficacy of treatment for rheumatoid arthritis.

Keywords

rheumatoid arthritis / activity monitoring / mobile health / mHealth / telemedicine / digital medicine / remote monitoring

References

[1] Erdes ShF. Definition of the term «Rheumatology»: do we need this and how do the eular and the acr look at this? Rheumatology Science and Practice. 2018;56(3):389–390. (In Russ.) doi: 10.14412/1995-4484-2018-389-390

[2] Эрдес Ш.Ф. Определение термина «ревматология»: нужно ли это нам и как на это смотрят EULAR и ACR? // Научно-практическая ревматология. 2018. Т. 56, № 3. С. 389–390. doi: 10.14412/1995-4484-2018-389-390

[3] Solomon DH, Rudin RS. Digital health technologies: opportunities and challenges in rheumatology. Nature Reviews Rheumatology. 2020;16:525–535. doi: 10.1038/s41584-020-0461-x

[4] Solomon D.H., Rudin R.S. Digital health technologies: opportunities and challenges in rheumatology // Nature Reviews Rheumatology. 2020. Vol. 16. P. 525–535. doi: 10.1038/s41584-020-0461-x

[5] Kim OT, Dadaeva VA, Telkhigova AA, Drapkina OM. Mobile medical applications: opportunities, challenges and prospects. Russian Journal of Preventive Medicine. 2021;24(7):96–102. (In Russ.) doi: 10.17116/profmed20212407196

[6] Ким О.Т., Дадаева В.А., Тельхигова А.А., Драпкина О.М. Мобильные медицинские приложения: возможности, проблемы и перспективы // Профилактическая Медицина. 2021. Т. 24, № 7. С. 96–102. doi: 10.17116/profmed20212407196

[7] Clinical guidelines — Rheumatoid arthritis. ID: KR250. Approved by the Ministry of Health of the Russian Federation. 2021. Available from: https://www.garant.ru/products/ipo/prime/doc/402775973/ (In Russ.)

[8] Клинические рекомендации — Ревматоидный артрит. ID: КР250. Утверждены Министерством здравоохранения РФ. 2021. Режим доступа: https://www.garant.ru/products/ipo/prime/doc/402775973/

[9] Venuturupalli RS, Sufka P, Bhana S. Digital Medicine in Rheumatology. Rheumatic Disease Clinics of North America. 2019;45(1):113–126. doi: 10.1016/j.rdc.2018.09.010

[10] Venuturupalli R.S., Sufka P., Bhana S. Digital Medicine in Rheumatology: Challenges and Opportunities // Rheumatic Disease Clinics of North America. 2019. Vol. 45, N 1. P. 113–126. doi: 10.1016/j.rdc.2018.09.010

[11] Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(10):e594–e610. doi: 10.1016/S2665-9913(23)00211-4

[12] Black R.J., Cross M., Haile L.M., et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021 // The Lancet Rheumatology. 2023. Vol. 5, N 10. P. e594–e610. doi: 10.1016/S2665-9913(23)00211-4

[13] Karateev AE, Polishchuk EY, Makhmudov HR, et al. How Russian patients with rheumatoid arthritis assess their condition: initial data from the OPTIMA (Patient Assessment of Severity, Outcomes and Medical Care in Arthritis) pilot study. Modern Rheumatology Journal. 2023;17(6):65–71. (In Russ.) doi: 10.14412/1996-7012-2023-6-65-71

[14] Каратеев А.Е., Полищук Е.Ю., Махмудов Х.Р., и др. Как российские пациенты с ревматоидным артритом оценивают свое состояние: первые данные пилотного исследования ОПТИМА (Оценка Пациентами Тяжести, Исходов и Медицинской помощи при Артрите) // Современная Ревматология. 2023. Т. 17, № 6. С. 65–71. doi: 10.14412/1996-7012-2023-6-65-71

[15] Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919

[16] Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force // Annals of the Rheumatic Diseases. 2010. Vol. 69, N 4. P. 631–637. doi: 10.1136/ard.2009.123919

[17] Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948–959. doi: 10.1136/annrheumdis-2016-210602

[18] Combe B., Landewe R., Daien C.I., et al. 2016 update of the EULAR recommendations for the management of early arthritis // Annals of the Rheumatic Diseases. 2017. Vol. 76, N 6. P. 948–959. doi: 10.1136/annrheumdis-2016-210602

[19] Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases. 2016;75(5):16–22. doi: 10.1136/annrheumdis-2015-207526corr1

[20] Stoffer M.A., Schoels M.M., Smolen J.S., et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update // Annals of the Rheumatic Diseases. 2016. Vol. 75, N 5. P. 16–22. doi: 10.1136/annrheumdis-2015-207526corr1

[21] Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the Rheumatic Diseases. 2016;75(8):1428–1437. doi: 10.1136/annrheumdis-2016-209201

[22] Schett G., Emery P., Tanaka Y., et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions // Annals of the Rheumatic Diseases. 2016. Vol. 75, N 8. P. 1428–1437. doi: 10.1136/annrheumdis-2016-209201

[23] Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid Arthritis: the Problems of Remission and Therapy Resistance. Rheumatology Science and Practice. 2018;56(3):263–271. (In Russ.) doi: 10.14412/1995-4484-2018-263-271

[24] Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии // Научно-практическая ревматология. 2018. Т. 56, № 3. С. 263–271. doi: 10.14412/1995-4484-2018-263-271

[25] Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(3):3–18. doi: 10.1136/ard-2022-223356corr1

[26] Smolen J.S., Landewé R.B.M., Bergstra S.A., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update // Annals of the Rheumatic Diseases. 2023. Vol. 82, N 3. P. 3–18. doi: 10.1136/ard-2022-223356corr1

[27] De Thurah A, Bosch P, Marques A, et al. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases. 2022;81(8):1065–1071. doi: 10.1136/annrheumdis-2022-222341

[28] De Thurah A., Bosch P., Marques A., et al. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases // Annals of the Rheumatic Diseases. 2022. Vol. 81, N 8. P. 1065–1071. doi: 10.1136/annrheumdis-2022-222341

[29] Marques A, Bosch P, de Thurah A, et al. Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases. RMD Open. 2022;8(1):e002290. doi: 10.1136/rmdopen-2022-002290

[30] Marques A., Bosch P., de Thurah A., et al. Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases // RMD Open. 2022. Vol. 8, N 1. P. e002290. doi: 10.1136/rmdopen-2022-002290

[31] Luo D, Wang P, Lu F, et al. Mobile Apps for Individuals With Rheumatoid Arthritis: A Systematic Review. JCR: Journal of Clinical Rheumatology. 2019;25(3):133–141. doi: 10.1097/RHU.0000000000000800

[32] Luo D., Wang P., Lu F., et al. Mobile Apps for Individuals With Rheumatoid Arthritis: A Systematic Review // JCR: Journal of Clinical Rheumatology. 2019. Vol. 25, N 3. P. 133–141. doi: 10.1097/RHU.0000000000000800

[33] Gandrup J, Ali SM, McBeth J, et al. Remote symptom monitoring integrated into electronic health records: A systematic review. Journal of the American Medical Informatics Association. 2020;27(11):1752–1763. doi: 10.1093/jamia/ocaa177

[34] Gandrup J., Ali S.M., McBeth J., et al. Remote symptom monitoring integrated into electronic health records: A systematic review // Journal of the American Medical Informatics Association. 2020. Vol. 27, N 11. P. 1752–1763. doi: 10.1093/jamia/ocaa177

[35] Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Annals of the Rheumatic Diseases. 2021;80(10):1278–1285. doi: 10.1136/annrheumdis-2021-220249

[36] Nikiphorou E., Santos E.J.F., Marques A., et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis // Annals of the Rheumatic Diseases. 2021. Vol. 80, N 10. P. 1278–1285. doi: 10.1136/annrheumdis-2021-220249

RIGHTS & PERMISSIONS

Eco-Vector